
Mifeprestone for Treatment of Hypercortisolism
Experts discuss the CATALYST study's evaluation of mifepristone for hypercortisolism patients with hard-to-manage type 2 diabetes, its mechanism of action, suitable patient populations, treatment approaches for those with adrenal tumors, and factors determining surgical candidacy.
Episodes in this series

Video content above is prompted by the following:
• Part 2 of the CATALYST study will assess the safety and efficacy of mifepristone treatment in patients with hypercortisolism who have difficult-to-control type 2 diabetes. Can you explain how mifepristone works to control hypercortisolism? For which patients would this treatment be appropriate?
• The catalyst study also showed that a quarter of the patients with hypercortisolism had an adrenal tumor. What would be the best way to treat these patients?
• Which patients would not be good candidates for surgery?


























































